

Chapter 13

REFERENCES

1. Mebis L, van den Berghe G. The hypothalamus–pituitary–thyroid axis in critical illness. *Neth J Med*. 2009;67:332–340.
2. Chiamolera MI, Wondisford FE. Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism *Endocrinology*. 2009;150:1091–1096.
3. Boelaert K, Franklyn JA. Thyroid hormone in health and disease. *J Endocrinol*. 2005;187:1–15.
4. de Loyd A, Bursell J, Gregory JW, Rees DA, Ludgate M. TSH Receptor activation and body composition. *J Endocrinol*. 2010;204:13–20.
5. Demers LM. Thyroid disease: pathophysiology and diagnosis. *Clin Lab Med*. 2004;24:19–28.
6. Topliss DJ, Eastman CJ. Diagnosis and management of hyperthyroidism and hypothyroidism. *Med J Aust*. 2004;180:186–193.
7. Stockigt JR. Free thyroid hormone measurement. A critical appraisal. *Endocrinol Metab Clin North Am*. 2001;30:265–289.
8. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T₄, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002; 87:489–499.
9. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. *J Clin Endocrinol Metabol*. 2005;90:5483–5488.
10. Surks MI, Goswami G, Daniels GH. The thyrotropin reference should remain unchanged. *J Clin Endocrinol Metabol*. 2005;90:5489–5496.
11. Hegedüs L. Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. *Endocrinol Metab Clin North Am*. 2009; 38:355–371.
12. Reid JR, Wheeler SF. Hyperthyroidism: diagnosis and treatment. *Am Fam Physician*. 2005;72:623–630.
13. Rehman SU, Cope DW, Senseney AD, et al. Thyroid disorders in elderly patients. *South Med J*. 2005; 98:543–549.
14. Habra M, Sarlis NJ. Thyroid and aging. *Rev. Endocrinol Metab Disord*. 2005;6:145–154.
15. Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. *Curr Heart Fail Resp*. 2008;5:170–176.
16. Bielecka-Dabrowa A, Mikhalidis DP, Rysz J, et al. Mechanism of Atrial fibrillation in hyperthyroidism. *Thyroid Res*. 2009;2:4.
17. Squizzato A, Gerdes VEA, Brandjes DPM, Büller HR, Stam J. Thyroid diseases and cerebrovascular disease. *Stroke*. 2005;36:2302–2310.
18. Papi G, Pearce EN, Braverman LE, Betterle C, Roti E. A clinical and therapeutic approach to thyrotoxicosis is with thyroid-stimulating hormone suppression only. *Am J Med*. 2005;118:349–361.
19. Klein I, Danzi S. Thyroid disease and the heart. *Circulation*. 2007;116:1725–1735.
20. Drugs for thyroid disorders. *Treat Guidel Med Lett*. 2009;84:57–64.
21. Gharib H, Tuttle RM, Baskin HJ, et al. Consensus Statement #1: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. *Thyroid*. 2005;15:24–28.
22. Hoogendoorn EH, den Heijer M, van Dink APJ, Hermus AR. Subclinical hyperthyroidism: to treat or not to treat? *Postgrad Med J*. 2004;80:394–398.
23. Sarlis NJ, Gourgiotis L. Thyroid emergencies. *Rev Endocrinol Metab Disord*. 2003;4:129–136.
24. Ringel MD. Management of hypothyroidism and hyperthyroidism in the intensive care unit. *Crit Care Clin* 2001;17:59–74.
25. Farwell AP, Braverman LE. Thyroid and antithyroid drug. Brunton LL, Lazo JS, parker KL, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New York, NY: McGraw-Hill; 2006:1530.
26. McDermott MT. In the clinic: hypothyroidism. *Ann Intern Med*. 2009;151:ITC61.
27. Kahaly G, Mohr-Kahaly S, Beyer J, et al. Left ventricular function analyzed by Doppler and echocardiographic methods in short-term hypothyroidism. *Am J Cardiol*. 1995;75:645–648.
28. Bengel FM, Nekolla SG, Ibrahim T, et al. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by position emission tomography and magnetic resonance imaging. *J Clin Endocrinol Metabol*. 2000;85:1822–1827.
29. Guo F, Xu T, Wang H. Early recognition of myxedematous respiratory failure in the elderly. *Am J Emerg Med*. 2009;27:212–215.
30. Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. *Crit Care*. 2008;12:R1.
31. Maquet E, Costagliola S, Parma, J, et al. Lethal respiratory failure and primary hypothyroidism in a term girl with a de novo heterozygous mutation in the T1-F1/NKX1.1 gene. *J Clin Endocrinol Metabol*. 2009;94:197–203.

32. Escobar-Morreale HF, Botella-Carretero JL, Escobar del Rey F, Morreale de Escobar G. Review: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. *J Clin Endocrinol Metab.* 2005;90:4946-4954.
33. Fliers E, Wiersinga WM. Myxedema coma. *Rev Endocrinol Metab Disord.* 2003;4:137-141.
34. Lu B, Wang KH, Nose A. Molecular mechanisms underlying neural circuit formation. *Curr Opin Neurobiol.* 2009;19:162-167.
35. Bootman MD, Fearnley C, Smyrniak I, MacDonald F, Roderick HL. An update on nuclear calcium signaling. *J Cell Sci.* 2009;122:2337-2350.
36. Dirksen RT. Sarcoplasmic reticulum-mitochondrial through-space coupling in skeletal muscle. *Appl Physiol Nutr Metab.* 2009;34:389-395.
37. Moe SM. Disorders involving calcium, phosphorous, and magnesium. *Prim Care Clin Office Pract.* 2008;35:215-237.
38. Kraft MD, Btaiche IF, Sacks GS et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. *Am J Health Syst Pharm.* 2005;35:1663-1682.
39. Makras P, Papapoulos SE. Medical treatment of hypercalcemia. *Hormones.* 2009;8:83-96.
40. Lehnart SE, Maier LS, Hasenfuss G. Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. *Heart Fail Rev.* 2009;14:213-224.
41. Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. *Cancer J.* 2006;12:47-53.
42. Shoback D. Clinical practice. Hypoparathyroidism. *N Engl J Med.* 2008;359:391-403.
43. Chrousos GP. Stress and disorders of the stress system. *Nat Rev Endocrinol.* 2009;5:374-381.
44. Michalakis K, Ilias I. Medical management of adrenal disease: a narrative review. *Endocr Regul.* 2009;43:127-135.
45. Nieman LK, Biller BMK, Findling JW, et al. The Diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2008;93:1523-1540.
46. Findling JW, Raff H. Clinical review: Cushing's syndrome: important issues in diagnosis and management. *J Clin Endocrinol Metab.* 2006;91:3746-3753.
47. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. *Endocrinol Metab.* 2008;93:3266-3281.
48. Schirpenbach C, Segmiller F, Diederich S, et al. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. *Dtsch Arztebl Int.* 2009;106:305-311.
49. Cooper MS, Stewart PM. Adrenal insufficiency in critical illness. *J Intensive Care Med.* 2007;22:348-362.
50. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. *J Clin Endocrinol Metab.* 2009;94:1059-1067.
51. Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochromocytoma: current approaches and future directions. *Oncologist.* 2008;13:779-793.
52. Karagiannis A, Mikhalidis DP, Athyros VG, et al. Pheochromocytoma: an update on genetics and management. *Endocr Relat Cancer.* 2007;14:935-956.
53. Manger WM. The protean manifestations of pheochromocytoma. *Horm Metab Res.* 2009;41:658-663.
54. Fassnacht M, Kreissl MC, Weismann D, et al. New targets and therapeutic approaches for endocrine malignancies. *Pharmacol Ther.* 2009;123:117-141.
55. Eisenhofer G, Siegert G, Kotzerke J, et al. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. *Horm Metab Res.* 2008;40:329-337.
56. Pacak K. Preoperative management of the pheochromocytoma patient. *J Clin Endocrinol Metab.* 2007;92:4069-4079.
57. Bondanelli M, Zatelli MC, Ambrosio MR, et al. Systemic illness. *Pituitary.* 2008;11:187-207.
58. Pereira O, Bevan JS. Preoperative assessment for pituitary surgery. *Pituitary.* 2008;11:347-351.
59. Loh JA, Verbalis JG. Disorders of water and salt metabolism associated with pituitary disease. *Endocrinol Metab Clin North Am.* 2008;37:213-234.
60. Seidman PA, Kofke WA, Policare R, et al. Anesthetic complications of acromegaly. *Br Anaesth J.* 2000;84:179-182.
61. Melamed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. *J Clin Endocrinol Metab.* 2009;1509-1517.
62. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2010;33(Suppl):S62-S69.
63. American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care.* 2010;33(Suppl):S11-S61.
64. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract.* 2009;15:540-559.
65. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and post prandial hyperglycemia in type 2 diabetes and therapeutic implications. *Endocr Rev.* 2007;28:253-283.
66. Via MA, Scurlock C, Adams DH, et al. An impaired postoperative hyperglycemic stress response is associated with increased mortality in cardiothoracic surgery patients. *Endocr Pract.* 2010;29:1-17.
67. Li L, Messina JL. Acute insulin resistance following injury. *Trends Endocrinol Metab.* 2009;20:429-435.
68. Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse-effects of adrenergic stress. *J Intensive Care Med.* 2009;24:293-316.
69. Mikulski T, Ziemba A, Nazar K. Metabolic and hormonal responses to body carbohydrate store depletion followed by high or low carbohydrate meal in sedentary and physically active subjects. *J Physiol Pharmacol.* 2010;61:193-200.
70. Kvetnansky R, Sabban EI, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. *Physiol Rev.* 2009;69:535-606.
71. deMontmolin E, Aboab J, Mansart A, et al. Bench-to bedside Review: beta-adrenergic modulation in sepsis. *Crit Care.* 2009;13:230.
72. Wright PD, Johnston IDA. The effect of surgical operation on growth hormone levels in plasma. *Surgery.* 1975;77:479.
73. Clarke RSJ. The hyperglycemic response to different types of surgery and anesthesia. *Br J Anaesth.* 1970;42:45.
74. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPD 35): prospective observational study. *BMJ.* 2000;321:405-412.

75. Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: population study using record linkage. *Diabetes Care*. 2000;23:211.
76. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus current concepts. *Am Med J*. 2004;116:11S-22S.
77. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. *Diabetes Care*. 2002;25:1129-1134.
78. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *Lancet*. 2002;359:2140-2144.
79. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. *Diabetes Care*. 1998;21:69-75.
80. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-2497.
81. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. *JAMA*. 1999;281:1291-1297.
82. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703-713.
83. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes: UKPDS 39. *BMJ*. 1998;317:713-720.
84. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. HOT study group. *Lancet*. 1998;351:1755-1762.
85. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560-2572.
86. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*. 2000;355:253-259.
87. Progress Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6205 individuals with previous stroke or transient ischemic attack. *Lancet*. 2001;358:1033-1041.
88. Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment and control in an adult type 1 diabetic population and a comparable general population. *Diabetes Care*. 2005; 28:301-306.
89. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. *Lancet*. 2002;360:7-22.
90. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis in the Scandinavian Simvastatin Survival Study. *Arch Intern Med*. 1999;159:2661-2667.
91. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med*. 1999;341:410-418.
92. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. *Lancet*. 2003;361:2005-2016.
93. Grundy SM, Cleeman JJ, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines III. *J Am Coll Cardiol*. 2004;44:720-732.
94. Arampatzis CA, Goedhart D, Serruys PW, et al. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—a Lescol Intervention Prevention Study (LIPS) substudy. *Am Heart J*. 2005;149:329-335.
95. Colwell JA, American Diabetes Association. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. *Am J Cardiovasc Drugs*. 2004;4:87-106.
96. American Diabetes Association. Aspirin therapy in diabetes. *Diabetes Care*. 2004; 27:S72-S73.
97. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study Research Group. *N Engl J Med*. 1989;321:129-135.
98. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. *Diabetes Care*. 2004;27:1954-1961.
99. Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. *Neurologist*. 2005;11:63-79.
100. Freeman R. Autonomic peripheral neuropathy. *Lancet*. 2005;365:1259-1270.
101. Kelkar P. Diabetic neuropathy. *Semin Neurol*. 2005;25:168-173.
102. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care*. 2005;28:956-962.
103. Vinik AI, Mehrabyan A. Diabetic neuropathies. *Med Clin North Am*. 2004;88:947-999.
104. Luukinen H, Airaksinen KE. Orthostatic hypotension predicts vascular death in older diabetic patients. *Diabetes Res Clin Pract*. 2005;67:163-166.
105. Cox DJ, Kovatchev BP, Gonder-Frederick LA, et al. Relationship between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. *Diabetes Care*. 2005;28:71-77.
106. Avanitakis R, Wilson RS, Scheider JA, et al. Diabetes mellitus and the progression of rigidity and gait disturbance in older persons. *Neurology*. 2004;63:966-1001.
107. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. *N Engl J Med*. 1993;329:977-986.
108. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA*. 2002;287:2563-2569.
109. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathy pain. *N Engl J Med*. 2005;352:1324-1334.

110. Tesfaye S, Chaturvedi N, Eaton SEM, et al. Vascular risk factors and diabetic neuropathy. *N Engl Med.* 2005;352:341-350.
111. American Diabetes Association. Nephropathy in diabetes. *Diabetes Care.* 2004;27(Suppl):79S-83S.
112. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* 2002;2(Suppl):S46-S75.
113. Writing Team for DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. *JAMA.* 2003; 290:2519-2167.
114. Sasaki K, Yoshimura N, Chancellor MB. Implication of diabetes mellitus in urology. *Urol Clin North Am.* 2003;30:1-12.
115. Kitabchi AE, Wall BM. Diabetic ketoacidosis. *Med Clin North Am.* 1995;79:9-37.
116. Coursin DB, Connery LE, Ketzler JT. Perioperative diabetic and hyperglycemic management issues. *Crit Care Med.* 2004;32(4 Suppl):S116-S125.
117. Warner ME, Contreras MG, Warner MA, et al. Diabetes mellitus and difficult laryngoscopy on renal and pancreatic transplant patients. *Anesth Analg.* 1998;86:516-519.
118. Hogan K, Rusy D, Springman SR, et al. Difficult laryngoscopy and diabetes mellitus. *Anesth Analg.* 1988;97:1162.
119. Reissell E, Orko R, Manunuksela E-L, et al. Predictability of difficult laryngoscopy in patients with long-term diabetes mellitus. *Anaesthesia.* 1990;45:1024.
120. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new worldwide definition. A consensus statement from the International Diabetes Federation. *Diabetes Med.* 2006;23: 469-480.
121. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National, Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation.* 2009;120:1640-1645.